Department of Urology, Paracelsus Medical University Salzburg, Salzburg, Austria.
Eur Urol. 2013 Feb;63(2):341-6. doi: 10.1016/j.eururo.2012.08.049. Epub 2012 Aug 29.
Eraser, a 1318-nm diode laser, has been used for 15 yr for resection of lung metastases. It was recently introduced in urology for small kidney tumors and for the treatment of benign prostatic obstruction.
To demonstrate on video our technique of Eraser laser enucleation of the prostate (ELEP) and report our experience.
DESIGN, SETTING, AND PARTICIPANTS: From June 2010 to October 2011, 43 consecutive patients were prospectively evaluated. All of them had lower urinary tract symptoms suggestive of benign prostatic obstruction and a mean prostate size of 59.9 ml (range: 34-89 ml) on transrectal ultrasound. Their mean prostate-specific antigen value was 3.4 ng/ml (range: 0.8-5.0 ng/ml); mean maximum flow rate (Q(max)), 6.9 ml/s (range: 2-11 ml/s); mean International Prostate Symptom Score (IPSS), 25.9 (range: 18-32); and mean postvoid residual (PVR), 170.5 ml (range: 60-330 ml).
The details of the technique are shown on video.
Success was defined as patients being able to void with improved IPSS, Q(max), PVR volume, and ameliorated quality of life.
The mean operating time was 67.0 ± 11.43 min. Mean serum hemoglobin was 15.1 ± 0.87 g/l before, and 14.39±0.94g/l after surgery. Mean blood loss was 115.90 ± 98.12 ml. No blood transfusions were required. All patients had their catheters removed within 2 d and were able to void spontaneously after this time. Significant improvements were noted in Q(max), quality of life, IPSS, and PVR volume from baseline to each follow-up time point. Based on the validated Clavien-Dindo system, we observed one grade 1d complication, one grade 2 complication, and one grade 3b complication.
ELEP is a safe and reproducible method for relieving bladder outflow obstruction and lower urinary tract symptoms. Its advantages include minimal blood loss, short catheterization time, and a brief hospital stay.
Eraser 是一种 1318nm 的二极管激光,已经用于切除肺转移 15 年。它最近被引入泌尿科,用于治疗小的肾脏肿瘤和良性前列腺增生。
通过视频展示我们的 Eraser 激光前列腺剜除术(ELEP)技术,并报告我们的经验。
设计、环境和参与者:从 2010 年 6 月到 2011 年 10 月,前瞻性评估了 43 例连续患者。所有患者均有下尿路症状,提示良性前列腺增生,并经直肠超声检查前列腺大小平均为 59.9ml(范围:34-89ml)。他们的平均前列腺特异性抗原值为 3.4ng/ml(范围:0.8-5.0ng/ml);平均最大尿流率(Qmax)为 6.9ml/s(范围:2-11ml/s);平均国际前列腺症状评分(IPSS)为 25.9(范围:18-32);平均剩余尿量(PVR)为 170.5ml(范围:60-330ml)。
技术细节在视频中显示。
成功定义为患者能够排尿,IPSS、Qmax、PVR 体积改善,生活质量提高。
平均手术时间为 67.0±11.43 分钟。术前平均血清血红蛋白为 15.1±0.87g/l,术后为 14.39±0.94g/l。平均失血量为 115.90±98.12ml。不需要输血。所有患者均在术后 2 天内拔除导尿管,在此时间后能够自行排尿。Qmax、生活质量、IPSS 和 PVR 体积均从基线显著改善至每个随访时间点。根据经验证的 Clavien-Dindo 系统,我们观察到 1 例 1 级并发症、1 例 2 级并发症和 1 例 3b 级并发症。
ELEP 是一种安全且可重复的缓解膀胱流出道梗阻和下尿路症状的方法。其优点包括出血量少、导尿管留置时间短、住院时间短。